Since the activation of renal ADAM17/TGFα signals occurs in human CKD of any etiology (92), calcitriol/VDR suppression of ADAM17 (38) could contribute to ameliorate CKD progression in hypertensive individuals (see Figure 3). Here, VDR is linked to chronic kidney disease.